Centre to eliminate malaria by 2030: Nadda

The Centre today set the target of eliminating malaria by 2030 after neighbouring countries like Sri Lanka and Nepal reported no deaths due to the vector-borne disease in the past several years.PTI | February 12, 2016, 08:15 IST

New Delhi: The Centre today set the target of eliminating malaria by 2030 after neighbouring countries like Sri Lanka and Nepal reported no deaths due to the vector-borne disease in the past several years.

"We are committed to achieving the target of elimination of malaria by 2030 which will require huge financial resources. We will effectively work with the development partners and civil society," Union Health MinisterJ P Nadda said.

Launching the National Framework for Malaria Elimination (2016-2030) here, the minister said 70 per cent of malaria cases and 69 per cent of malaria deaths among South East Asian Region countries, occur in India.

"The objective of the framework is to reduce the incidence of malaria to less than one case per 1,000 population per year in all states and UTs by 2024. We would ask all state governments to include malaria eradication programme in their policy matters," he said.

Quoting statistics, Nadda said more than 80 per cent of the country's population live in 'malaria transmission high-risk areas' of around 200 districts covering states like Andhra Pradesh, Chhattisgarh, Gujarat, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, West Bengal and the seven northeastern states.

"Presently, 80 per cent of malaria is prevalent among 20 per cent of the people classified as 'high risk', although approximately 82 per cent of the country's population live in malaria transmission risk areas," he said.

Under the framework for malaria elimination, the country has been divided into three categories on the basis of annual parasite incidences and key interventions have been identified to achieve the goal, the Union Minister added.

Sri Lanka has reported no malaria deaths in the last one decade, while in Nepal no death due to the vector-borne disease took place since 2012.

Subscribe ETHealthworld Newsletter

Lyrica, known generically as pregabalin, was originally developed for epilepsy but further research showed it could also help patients suffering from neuropathic pain, which soon became its main market.

With this acquisition, Nephroplus will further strengthen its servicing capacity as the dominant dialysis centre network and will have a presence in 18 states of India with 176 centers across 97 cities.